Brineura

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares have historically outperformed during product launches, and Credit Suisse’s Kennen MacKay expects the Brineura launch in Q2:17 and upcoming launches of Vosoritide and PEG-PAL to drive earnings as well as investor interest. MacKay initiated...